Dyne Therapeutics recently joined PPMD for a community webinar on the DELIVER clinical trial evaluating DYNE-251. The Dyne team provided the latest updates on the Phase 1/2 global DELIVER study of the company’s investigational therapy for individuals living with Duchenne who are amenable to exon 51 skipping.
Watch the recording
The post Watch: Dyne Therapeutics — The Clinical Impact of the FORCE™ Platform for Duchenne (Webinar Recording) appeared first on Parent Project Muscular Dystrophy.